The earnings call highlighted significant advancements in Co-Diagnostics' Co-DX PCR platform development, supported by major grants and upcoming clinical evaluations. However, these positives were overshadowed by a sharp revenue decline and increased losses, indicating financial challenges.

Company Guidance

During the second quarter of 2025 earnings call, Co-Diagnostics provided detailed guidance on the progress and anticipated timelines for their Co-DX PCR testing platform. The company is on track to initiate clinical evaluations for several tests by the end of 2025, including those for COVID-19, a 4-plex respiratory panel, tuberculosis (TB), and an HPV 8-type multiplex panel. These tests are expected to undergo clinical trials in sequence, beginning with the COVID-19 test, followed by the 4-plex respiratory panel, TB, and HPV tests. Co-Diagnostics aims to submit a 510(k) application to the FDA for the COVID-19 test after clinical evaluations are completed, with an anticipated commercial launch by mid-2026. The company is focusing on point-of-care markets, such as physician offices, skilled nursing facilities, and pharmacies in the United States, while targeting primary healthcare centers in India. Financially, Co-Diagnostics reported a revenue decrease to $0.2 million in Q2 2025, compared to $2.7 million in the same period of 2024, with total operating expenses also declining to $8.2 million from $10.1 million. The company ended the quarter with $13.4 million in cash, equivalents, and marketable investment securities, and plans to meet its capital requirements through equity, debt financing, and grant funding.

Advancement of Co-DX PCR Platform

Co-Diagnostics has made steady advancements on its Co-DX PCR point-of-care platform, with plans to initiate clinical evaluations for all tests in the pipeline during 2025.

Grants from Major Organizations

The development of the TB and HPV tests is supported by grants from the Bill & Melinda Gates Foundation, and the 4-plex respiratory panel is supported by a grant from the National Institute of Health's RADx Tech program.

Progress on TB Test

Preliminary studies for the Co-DX PCR MTB test are completed or in process, with plans to begin clinical evaluations in India and South Africa by the end of 2025.

Upcoming Clinical Evaluations

Co-Diagnostics plans to start clinical evaluations for the COVID-19, ABCR 4-plex, TB, and HPV tests in 2025, with the COVID-19 test already beginning site visits and training.

Innovative Cloud-Based Analysis

The Co-DX PCR platform includes a cloud-based analysis feature that provides epidemiological data to health departments, a feature supported by the Bill & Melinda Gates Foundation and the National Institute of Health's RADx Tech program.

Co-Diagnostics (CODX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CODX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.15 / -	-0.32	―	―	―
Aug 14, 2025	2025 (Q2)	-0.25 / -0.23	-0.25	8.00% (+0.02)	―
May 08, 2025	2025 (Q1)	-0.27 / -0.24	-0.31	22.58% (+0.07)	―
Mar 27, 2025	2024 (Q4)	-0.34 / -0.36	-0.494	27.13% (+0.13)	―
Nov 07, 2024	2024 (Q3)	-0.33 / -0.32	-0.2	-60.00% (-0.12)	―
Aug 08, 2024	2024 (Q2)	-0.34 / -0.25	-0.31	19.35% (+0.06)	―
May 09, 2024	2024 (Q1)	-0.21 / -0.31	-0.2	-55.00% (-0.11)	―
Mar 14, 2024	2023 (Q4)	-0.20 / -0.49	-0.18	-174.44% (-0.31)	―
Nov 09, 2023	2023 (Q3)	-0.29 / -0.20	-0.04	-400.00% (-0.16)	―
Aug 10, 2023	2023 (Q2)	-0.24 / -0.31	-0.08	-287.50% (-0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CODX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.26	$0.29	+11.54%
May 08, 2025	$0.36	$0.34	-5.56%
Mar 27, 2025	$0.39	$0.32	-17.95%
Nov 07, 2024	$1.18	$1.14	-3.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Co-Diagnostics Inc (CODX) report earnings?

Co-Diagnostics Inc (CODX) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Co-Diagnostics Inc (CODX) earnings time?

Co-Diagnostics Inc (CODX) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CODX EPS forecast?

CODX EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing